ICU Medical Inc (OQ:ICUI)
Business Focus: Medical Equipment, Supplies & Distribution
| Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 951 Calle Amanecer SAN CLEMENTE CA 92673 |
| Tel: | 1-646-2771254 |
| Website: | https://www.icumed.com |
| IR: | See website |
| Key People | ||
| Vivek Jain Chairman of the Board, Chief Executive Officer | Brian Michael Bonnell Chief Financial Officer, Treasurer | Christian B. Voigtlander Chief Operating Officer |
| Virginia Sanzone Corporate Vice President, General Counsel, Secretary | Daniel Woolson Corporate Vice President, General Manager - Infusion Systems | |
| Business Overview |
| ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needle free IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy product include Portex BLUselect PVC tracheostomy tubes. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, ICU Medical Inc revenues decreased 1% to $2.26B. Net loss decreased 60% to $29.7M. Revenues reflect Vital Care segment decrease of 4% to $661M, Consumables segment decrease of 1% to $969.1M, United States segment decrease of 1% to $1.44B, APAC segment decrease of 6% to $241.7M. Lower net loss reflects Restructuring Charges/Provisions decrease of 42% to $41.3M (expense). |
| Employees: | 14,000 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $3,710M as of Dec 31, 2023 |
| Annual revenue (TTM): | $2,259M as of Dec 31, 2023 |
| EBITDA (TTM): | $293.92M as of Dec 31, 2023 |
| Net annual income (TTM): | -$29.66M as of Dec 31, 2023 |
| Free cash flow (TTM): | $72.53M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $1,377M as of Dec 31, 2023 |
| Shares outstanding: | 24,365,082 as of Mar 19, 2024 |
| Index Membership: | S&P 600 Small Cap |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.